Boehringer Ingelheim

This study tested an experimental drug called BI 765845 in 160 adults who had just had a heart attack. Participants received either the drug or a placebo, and doctors measured heart damage using MRI scans over 3 months. The trial was terminated early, so it is unclear if the drug…

This study looks at the long-term safety and effectiveness of spesolimab for people with hidradenitis suppurativa (HS), a painful skin condition. Participants who completed a prior spesolimab study receive injections under the skin every 2 weeks for about 1.5 years. The goal is t…

This study looked at the safety and effectiveness of Pradaxa oral pellets in children aged 3 months to 12 years who had blood clots (venous thromboembolism). The goal was to see how often bleeding or new clots occurred in real-world use. Only 5 children were enrolled before the s…

This early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…

This study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …

This study tested a single dose of an inhaled gene therapy called BI 3720931 in adults with cystic fibrosis who cannot take standard CFTR modulator drugs. The trial was in two phases and included only 5 participants. It was terminated early, so we do not have full results on safe…

This study looked at the long-term safety of a medicine called iclepertin in adults with schizophrenia who had already finished earlier studies. About 1,356 participants took iclepertin tablets once a day for one year, along with their usual schizophrenia medications. The main go…

This study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…

This early study tested an experimental drug called BI 765883, alone or with chemotherapy, in 8 adults with advanced pancreatic cancer. The goal was to find a safe dose and see if it helps shrink tumors. The trial was terminated early, so results are limited.

This study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…

This study tested whether the drug Avenciguat, taken alone or with empagliflozin, can lower high blood pressure in the portal vein (the main vessel to the liver) in people with cirrhosis. About 90 adults with cirrhosis from hepatitis or fatty liver disease were enrolled. The tria…

This study tested whether adding an experimental oral drug (BI 706321) to the standard treatment ustekinumab helps people with moderate to severe Crohn's disease. About 49 adults took either the combination or a placebo plus ustekinumab for 12 weeks, followed by ustekinumab alone…

This study tested a drug called Avenciguat in adults with liver cirrhosis and high blood pressure in the portal vein (the main vessel to the liver). Participants took either a low or high dose of Avenciguat or a placebo twice daily for 24 weeks. The goal was to see if the drug co…

This study tested an experimental drug called BI 1839100 in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) who have a chronic cough. Participants took different doses of the drug or a placebo for 12 weeks. The goal was to see if the drug c…

This study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.

This study looked at 88 adults with connective tissue disease-related lung scarring who were prescribed nintedanib. Researchers measured changes in lung function and tracked cough and breathlessness using a questionnaire over 24 months. The goal was to see if improvements in lung…

This early-stage trial tested the safety and how the body processes a single dose of the experimental drug BI 1569912 in 68 healthy men. The study also looked at how food affects drug absorption. The trial was terminated, so results are limited.

This early-stage trial tested the safety and how the body handles a new drug called BI 3009947 in 40 healthy men. The study was terminated early. It was not designed to treat any disease, but to gather basic information about the drug's safety and processing in the body.

This study looks at how healthy men absorb, break down, and eliminate the experimental drug BI 1819479. It involves taking the drug by mouth and, in one part, receiving a tiny radioactive tracer through a vein. The goal is purely to gather information, not to treat any disease. T…

This early-stage trial aimed to check the safety and how the body handles a new drug called BI 3731579. It involved 30 healthy adults who took multiple doses over 15 days. The study was terminated early, and no results are available. Since it only tested safety in healthy people,…

This early-phase study aimed to use PET imaging to track how a new drug (BI 754111) spreads in the body and reaches tumors in people with advanced non-small cell lung cancer or head and neck cancer. Only 8 participants were planned, and the study was terminated early. The main go…

This early-stage trial tested the safety and how the body processes a new drug called BI 706321 in healthy Japanese and Chinese men. The study was terminated early, so no results are available. It was designed to check for side effects and measure drug levels in the blood.

This early-stage trial in 8 healthy men aims to understand how the experimental drug BI 1839100 is processed by the body. Part A tracks the drug and its radioactive label in urine and feces after an oral dose. Part B compares how much of the drug reaches the bloodstream when give…